Pharmaceutical Executive-05-01-2010

One year after the rash of pharma megamergers, Pharm Exec's annual listing of the industry's top-selling companies looks a little different. Find out who disappeared from the list, and what up-and-coming companies finally broke into the top 50.

One Pill Makes You Better?

Timely and accessible information can help break through the firewall of regulation.

The Orphan Drug Act of 1983 has been a roaring success. So why is everybody trying to mess with it?

The new world of mobile applications is sparking creative platforms for reaching consumers and physicians.

How will US healthcare reform affect drug pricing, revenue, and compliance?

Cash-rich Big Pharmas are hedging their bets to cover both segments under the rubric of "diversification." If it sticks to the wall, then buy it.

The three-way race for control of Parliament leaves the future of the British pharmaceutical industry in the balance.

A panel of bankers and industry executives discuss what's ahead in deals for 2010.

Marketers must focus on getting busy women the help they need in making critical decisions about their healthcare.

Under the new healthcare regime, pharma will ante up fees and rebates in return for expanded sales and safeguards.